Aksamit Timothy


Adjunct Assistant Professor of Biomedical Science
B.S., University of Illinois
M.D., Northwestern University School of Medicine

Dr. Aksamit is board certified in pulmonary disease and critical care medicine as well as internal medicine. He currently is an associate professor of medicine and consultant at the Mayo Clinic in Rochester, Minnesota.
After completion of residency training in internal medicine, pulmonary diseases, and critical care medicine including a chief residency at the University of Iowa in Iowa City, Dr. Aksamit was in private practice for six years in Madison, Wisconsin prior to joining the Mayo Clinic staff in 1998.
His professional interests are in pulmonary diseases and critical care medicine. He has previously served as the director of the medical intensive care unit at St. Mary’s Hospital, Mayo Clinic, Rochester, Minnesota for six years.. He has co-authored an international position statement by the American Thoracic Society and Infectious Disease Society of America on the diagnosis and treatment of nontuberculous mycobacterial disease, and is a co-founding member of an international nontuberculous consortium, NTM-NET. Dr. Aksamit has assisted in the development and implementation of a collaborative tuberculosis clinic project between Mayo Clinic and the Olmsted County Public Health Department, and has served as the medical director since its inception in 2001. Other positions held include chair of the State of Minnesota Tuberculous Advisory Committee as well as director of the Mayo Mycobacterial and Bronchiectasis Clinic. Dr. Aksamit has participated in the CDC-sponsored Heartland National TB Center in San Antonio, Texas, as a faculty member, advisory committee member, and medical consultant. Collaborative efforts by Dr. Aksamit have resulted in Mayo Clinic’s position as one of the founding members of the national Bronchiectasis Research Registry, and he serves as the chair of the Registry’s advisory committee.

Download COI Disclosure

Aliberti Stefano

Stefano Aliberti is Associate Professor in Respiratory Medicine at the University of Milan and consultant at the Policlinico University Hospital, Milan, Italy. He received his medical degree from the University of Milan and completed his clinical research training at the University of Louisville, KY, USA, working as member of the Community-Acquired Pneumonia Organization Database. Most of his research over the past ten years has been focused on both acute and chronic respiratory infections. He is currently Head of the Respiratory Infections Assembly of the European Respiratory Society, co-funding member of both the European Registry (EMBARC) and the Italian Registry (IRIDE) of adult patients with bronchiectasis. He leads a multidisciplinary team of physicians and respiratory physiotherapists taking care bronchiectasis patients and those with NTM at the Policlinico Hospital.
Download COI Disclosure

Al Jahdali Hamdan

I obtained my MBBS from king Abdulaziz University 1987. I completed my training in internal medicine specialty at university of Ottawa- Canada from year 1990-1994. I obtained my American Board of internal medicine 1993 and Canadian board of internal medicine 1994. I joined McGill University 1994, where I completed my pulmonary fellowship training 1994-1995 and sleep medicine 1996. I obtained my American board of pulmonary medicine 1996 and Canadian Board of pulmonary medicine 1997. I joined the internal medicine department and pulmonary division 1997 at King Abdulaziz medical city as consultant internal medicine/pulmonary and sleep medicine.
I have significant teaching commitments in both department of medicine and respiratory medicine. I served as deputy program director and as program director for medical residency program year 1998/1999. I have the honor to establish the first fellowship-training program in pulmonary medicine at King Abdulaziz university year 1999-2000, then to establish the combined pulmonary fellowship training program under umbrella of Saudi medical council. 2000. I served as pulmonary fellowship training program director from 1999- to 2009.
I have also established sleep disorders center at KAMC 2003. I have been the pulmonary head division and the medical director of sleep disorders center since year 2000. I have been appointed as honoree assistant clinical professor at King Saud University from 1997 to 2005.
I have been the chair of Riyadh chest club monthly meeting from 1998-2008. I have the Honor to be one of five founder members, who establish Saudi Thoracic Society and to serve as vice president from year 2005-2008.
I received many other award and recognition; during my training in Canada I was awarded “Dr Pare” award for the best pulmonary fellow in training. In year 2008/2009, I awarded King Abdullah international medical research center award for 2008/2009 researcher.
I work mainly as a clinician, however also I am interested in doing research as well. I have been able to publish more than 110 papers including research results and reviews. My research involves extensive collaboration with colleagues from other disciplines, including microbiology, nephrology, ICU, internal medicine, public health; sleep medicine, and biostaticians.
I have also supervised graduate students from KSU-HS and resident from family medicine training program. I serve as member of asthma research chair at King Saud University since 2008.
Recently I got interested in Bioethics, I have joined Bioethics Master Program at KAMC for 2years
I have joined the faculty of King Saud University for health Science 2005 as assistant professor and promoted to associate professor 2010 and as full professor of medicine August 2014. I have been appointed as adjunct professor at McGill University since august 2010. In addition, I have been appointed as deputy chair of department of medicine since August 2010, head of pulmonary division since 2002, director of sleep disorders center since 2003, and chair of corporate pharmacology and therapeutic committee at ministry on national guard since 2011.

Barker Alan


Dr. Alan Barker is Professor of Medicine, Pulmonary and Critical Care, at the Oregon Health and Science University, Portland, Oregon, USA. He has been involved in clinical research involving bronchiectasis for over 30 years. Special interests include the potential role of inhaled antibiotics. He has been a lead investigator in several of the largest clinical trials in bronchiectasis.

Download COI Disclosure

Basavaraj Ashwin

Basavaraj-wbc Ashwin Basavaraj is an Assistant Professor of Medicine at New York University School of Medicine. He received his medical degree from New York Medical College, and his internal medicine residency training at Georgetown University Hospital. He completed his pulmonary and critical care fellowship training at New York University School of Medicine. During his fellowship training, Dr. Basavaraj became involved in research studying non-tuberculous mycobacteria (NTM) and bronchiectasis. Specifically he was interested in analyzing clinical outcomes in patients managed without NTM antibiotic therapy. After his fellowship training, he stayed on as faculty at NYU, continuing his research in NTM and bronchiectasis. Dr. Basavaraj has been one of the course directors for NYU’s annual Non-Tuberculous Mycobacteria Symposium, and has also directed its NTM patient education programs. He has lectured nationally on bronchiectasis and NTM at the American Thoracic Society and American College of Chest Physician conferences, and has also appeared on Doctor Radio SiriusXM discussing NTM and bronchiectasis.

Dr. Basavaraj’s current research interests include the microbiome of NTM, the association of reflux and aspiration with bronchiectasis, and the clinical outcomes of NTM patients managed with chest physical therapy. He sees patients both at NYU Langone Medical Center and Bellevue Hospital Center. Dr. Basavaraj also serves as an Assistant Program Director for the Pulmonary and Critical Care fellowship program at NYU, an Assistant Director of the NYU Bronchiectasis Program, and the Director of Bronchoscopy at Bellevue Hospital Center.

Download COI Disclosure

Blasi Francesco

blasi Francesco Blasi, MD, FERS, is Professor of Respiratory Medicine and Head of the Department of Pathophysiology and Transplantation at the University of Milan, Italy, as well as Head of Cardiothoracic Unit IRCCS Fondazione Cà Granda Ospedale Maggiore Milan.
His research interests include the effects of atypical bacterial infection on cellular immunity in chronic bronchitis, and the role of atypical bacteria and viral infection in asthma onset.
He is also interested in the role of antibiotics in the treatment of chronic obstructive pulmonary disease (COPD) exacerbations and asthma. He is actively working on pneumonia and tuberculosis research trials.
Professor Blasi has published more than 230 papers in international journals.
Download COI Disclosure

Bonini Sergio

Sergio Bonini is Professor of Internal Medicine at the Second University of Naples and Research Associate at the Italian National Research Council (CNR), Institute of Translational Pharmacology, Rome.
Since 2013 he is Expert-on-Secondment, Advisory Function-Senior Medical Officer at the European Medicines Agency and Member of the Scientific Committee of the Italian Embassy in London.
M.D. degree at the University of Rome “La Sapienza” in 1971. Board certified in Allergology and Clinical Immunology (1972), Gastroenterology (1973) and Internal Medicine (1984).
Research of Prof. Bonini has mainly focused on allergic and autoimmune diseases (Charles Blackley Awardee in 2010) as well as on the role of Nerve Growth Factor in allergic inflammation and tissue remodelling.
Scientific production of Prof. Bonini includes approx. 500 publications (more than 250 indexed by ISI). H-index > 45. The most cited papers include the original description of a late-phase reaction in the eye, the first report on the potential relevance of NGF in asthma and allergic inflammation, the description of genetic and environmental factors (infections, smoking, physical activity) influencing allergy phenotypes.
Prof. Bonini is President of the Italian Medical Society in Great Britain since June 2016. He is Past-President (1998-2001) of the European Academy of Allergology and Clinical Immunology (Secretary General 1986-1998 and Honorary member of the Rumenian Academy of Sciences and of the Belgian, Hungarian and Argentinian Societies of Allergology and Clinical Immunology. He has been part of several international (WHO, IAACI-WAO, EAACI, AAAAI, European Medicines Agency) and national (Ministry of Health, Italian Drug Agency) expert board panels. Co-founder of Allergy, he is editorial board member and/or referee of several journals. Wide experience in congress organization.
Download COI Disclosure

Bradley Judy

Prof Judy Bradley is the Director Northern Ireland Clinical Research Facility Queen’s University Belfast. Previous to this appointment I held a Joint appointment in Physiotherapy, between Ulster University and Belfast Health and Social Care Trust. I have been co-lead of the Northern Ireland Clinical Research Newtork (Respiratory Health) since its inception in 2008 and as part of this role I have been responsible for its strategic direction as well as operationalizing the infrastructure to support a wide range of pharma-sponsored/investigator-led clinical and laboratory trials in Northern Ireland.

My area of major research interest is respiratory disease and I have a special interest in bronchiectasis, particularly in the evaluation of treatment therapies as well as outcome measures. I am interested in interdisciplinary translational research collaborations that focus on using a personalised therapy approach focused on making a real difference to patients lives.

I have been involved in Bronch UK which is a MRC funded multidisciplinary academic collaboration in bronchiectasis. Within this collaboration I am lead on a large study examining the clinimetric properties of a range of endpoints in bronchiectasis. I have also recently been awarded an NIHR grant to lead a clinical trial exploring the effectiveness of Hypertonic tonic saline and Carbocistine in bronchiectasis.

Download COI Disclosure

Castellani Carlo

Dr Carlo Castellani trained in the Pediatric Department of the University of Verona. He is registered Pediatrician and registered Medical Geneticist. In 1992 he joined the Verona Cystic Fibrosis Centre, where he is now in charge of the Clinical Genetics and Neonatal Screening Services and of the adult section .


In Italy he has served on a number of committees including the board of the Italian Cystic Fibrosis Working Group and the Commission on Patterns of Genetic Analysis for Cystic Fibrosis. He is presently past President of the Italian Cystic Fibrosis Society.


His international functions include membership of the CF Diagnostic Network and participation in scientific committees of the European Cystic Fibrosis conference and North American Cystic Fibrosis conference. He has been advisor in the Subcommittee on Newborn Screening for Cystic Fibrosis of the Clinical and Laboratory Standard Institute. Dr Castellani has started and chaired the ECFS Working Group on Neonatal Screening and has been board member, secretary and vicepresident of the European Cystic Fibrosis Society. He has led several several ECFS consensus initiatives which produced guidelines on CFTR mutation analysis in clinical practice, CF neonatal screening, CF carrier screening and CF Standards of Care. Dr Castellani is a member of the CFTR2 core team.


His main clinical and research interests lie in CF epidemiology, genotype/phenotype correlation, CF diagnosis, CFTR-related disorders, neonatal screening and CF adult care. He has published in several peer reviewed jourmals, including JAMA, Nature Genet, the Lancet, Am J Respir Crit Care Med, Am J Hum Genet, Am J Med Genet, J of Pediatr, J Med Genet, Pancreatology, Acta Paediatr, Thorax, Pediatric Pulmonol, J Mol Med, Am J Gastroenterol, Am J Epidemiol, Eur Resp J, Hum Mutation, Hum Genet, Arch Dis Childhood, J Cyst Fibros and Eur J Hum Genet.

Download COI Disclosure

Chalmers James D.

chalmers Dr James Chalmers is Clinical Senior Lecturer and Honorary Consultant at the University of Dundee in the UK. He runs a regional specialist clinic caring for more than 600 patients with bronchiectasis. He runs a research group primarily focussed on developing novel diagnostics and treatments for bronchiectasis funded by the Scottish Government, Medical Research Council, Wellcome Trust, European Union, Charities and Industry.
He is chair of the European Bronchiectasis Registry and has chaired the upcoming ERS bronchiectasis guidelines along with Dr Eva Polverino. He is associate editor of the European Respiratory Journal, is on the International advisory board of the Lancet Respiratory Medicine, is secretary of the European Board for Accreditation in Pneumology, is chair of the British Thoracic Society Respiratory Infections Speciality advisory group and holds a number of other major society/committee appointments.
Download COI Disclosure

Coulter Tanya

”Dr Tanya Coulter (FRCPath, PhD) is a Consultant Immunologist working in The Regional Immunology Service of Northern Ireland, UK. This service investigates and manages patients with immune deficiencies and bronchiectasis and provides joint immunology and respiratory clinics for children and adults with immune deficiency and bronchiectasis. Her research interests include Activated PI3-kinase Deficiency syndromes.”
Download COI Disclosure

Daley Charles

Charles L. Daley, M.D., is Professor of Medicine at National Jewish Health (NJH) and the University of Colorado Denver. He is Chief of the Division of Mycobacterial and Respiratory Infections and Director of the Nontuberculous Mycobacteria (NTM) Center of Excellence at NJH. Dr. Daley works closely with the World Health Organization (WHO) and the Stop TB Partnership in the global control of drug-resistant tuberculosis. He is immediate past-Chair of the Strategic and Technical Advisory Group (STAG)-TB for WHO and Chair of the Global Drug Resistance Initiative, a working group of the Stop TB Partnership and advisory body to the WHO Global TB Department. He has served on expert panels for the WHO, Centers for Disease Control and American Thoracic Society: He is Chair of the ATS/IDSA/ERS/ESCMID NTM Guidelines revision committee and serves on the guideline committees for the diagnosis of TB, treatment of TB and treatment of MDR-TB for both the ATS and WHO. Dr. Daley has been recognized as one of the “Best Doctors in America” by U.S. News & World Report and Castle Connolly and he recently received the World Lung Health Award given by the ATS. His academic interests include global health policy and clinical and translational research in tuberculosis and NTM.
Download COI Disclosure

Elborn Stuart J.


His main focus is Cystic Fibrosis focused on understanding pathophysiology of infection and inflammation and the translation of new therapies into clinical practice. This programme of work is undertaken with laboratory and clinical collaborators in QUB. This includes a significant commitment from the NICRN (Respiratory Health) where I am PI on 6 current clinical trials. I have smaller programmes with others in COPD, bronchiectasis, lung cancer including clinical trials. His research is funded by grants from government agencies, charitable bodies, industry and money raised from clinical trials. He have developed a clinical trials network for Respiratory Health funded by the Northern Ireland Research and Development Office.
In all there research I endeavour to bring scientists and clinicians together to promote inter-disciplinary research. He have been successful in developing programmes of research across disciplines, hospitals and universities in Northern Ireland and across the UK and Europe.

Download COI Disclosure

Goeminne Pieter

pieter-wbc2 Pieter Goeminne is a respiratory physician and staff member at AZ Nikolaas, Sint-Niklaas, Belgium. He achieved his PhD on the topic of bronchiectasis in 2013 at the University of Leuven and remains a scientific collaborator at the University Hospital of Leuven, Belgium where he supports research on bronchiectasis. He is the chair of the Infectious Disease Working group of the Belgian Respiratory Society and is the author of international peer-reviewed papers. He is also a reviewer for several journals and actively takes part in the EMBARC project.
Download COI Disclosure

Greulich Timm

Dr. Timm Greulich is presently a Senior Physician at the University Hospital Giessen and Marburg for Internal Medicine and Respiratory Diseases.

He attended his medical education at the Philipps-University Marburg, the Brethren College, North Manchester (Indiana, USA), and the University Hospital Singapore. He graduated from the University of Marburg and did his doctorial thesis at the Philipps-University Marburg, Germany.

He began his career in Emergency Medicine and later went into Internal Medicine, Pulmonary Medicine, and Sleep Medicine. His research focuses on Alpha-1-Antitrypsin Deficiency (AATD) and other subtypes COPD and asthma.

He is an active member of the Writing Committee for the National Guidelines for Asthma and has published numerous articles on COPD and AATD

Download COI Disclosure

Haworth Charles

Charles Haworth is Director of the Cambridge Centre for Lung Infection at Papworth Hospital. He trained at the Manchester Adult Cystic Fibrosis Centre, the Royal Brompton Hospital and at Hammersmith Hospital, before moving to Cambridge in 2003. He co-authored the US CF Foundation and European CF Society NTM guidelines published in Thorax in December 2015 and is co-chair of the BTS NTM guidelines committee. He is also a member of the BTS bronchiectasis and ERS bronchiectasis guidelines committees. He collaborates with Professor Andres Floto at the University of Cambridge on NTM related studies and is a member of the European Union funded iABC and CFMATTERS consortia. He is co-chief investigator of three current international novel therapy clinical trials in people with bronchiectasis. He is also the site Principal Investigator for the European Cystic Fibrosis Society Clinical Trials network and is a member of the CF Foundation Data Safety Monitoring Board.
Download COI Disclosure

Loebinger Michael

Dr. Michael Loebinger is a Consultant Respiratory Physician at the Royal Brompton Hospital, UK with a specialist interest in respiratory infections, non tuberculous mycobacteria and bronchiectasis. He co-chairs the BTS bronchiectasis guideline committee and is on the steering committee for the BTS non-tuberculous mycobacteria and ERS bronchiectasis guidelines. He is a founding member of the UK and European clinical and research bronchiectasis networks and sits on the ERS Respiratory Infection Education task force. He chaired the infection special advisory group for the BTS. He also holds an honorary senior lecturer position at Imperial College and supervises PhD, MSc and medical students.
Download COI Disclosure

Martinez Garcia Miguel Angel

Miguel Ángel Martínez García. 47 years old. MD, pHD

Section Head of Pneumology. Research coordinator of the Respiratory Disorders Area and coordinator of the Sleep-Disordered Breathing Unit of the University and Polytechnic La Fe Hospital. Valencia. Spain. Associated Editor of the European Respiratory Journal. Director of the Integrated Research Program (PII) of bronchiectasis from SEPAR (Spanish Society of Pneumology). Current coordinator of the 2017 Spanish Guidelines in bronchiectasis and the Spanish National Registry of bronchiectasis (RIBRON). 152 original publications or reviews. Master in clinical management. Editor of seven books on bronchiectasis and sleep apnoea. Twelve research awards. Current research areas of interest: Relationship between bronchiectasis and other airway disorders (COPD and asthma), clinical tools in bronchiectasis, and relationship between cardiovascular disorders and cancer with sleep apnoea.

Download COI Disclosure

McDonnell Melissa

Dr. Melissa McDonnell is an Academic Specialist Registrar in Respiratory Medicine in Galway University Hospitals and the National University of Ireland, Galway. She has been awarded funding from the European Respiratory Society and Health Research Board, Ireland to complete research in the field of bronchiectasis. Dr. McDonnell’s primary clinical and research interests focus on bronchiectasis, chronic obstructive pulmonary disease and pulmonary infections. She has presented her research extensively at national and international congresses and has published in several international peer-reviewed journals.
Download COI Disclosure

Morgan Lucy

Lucy is a Respiratory Physician working in clinical academic practice in Sydney. She has 20 year’s experience in the care of patients with chronic respiratory infections and is Chair of the Australasian Bronchiectasis Consortium, a proud antipodean member of the EMBARC program and co-convenor of the WBCII. Lucy is the Director of the Australian Centre for Ciliary Structure and Function and the multidisciplinary PCD Management service at Concord Hospital. She is a passionate advocate for patients with chronic lung disease and holds executive positions on the TSANZ and Lung Foundation Australia.
Download COI Disclosure

O’ Donnell Anne

Cv and photo not available
Download COI Disclosure

Olivier Kenneth

Dr Olivier is a senior clinician and chief of the Pulmonary Clinical Medicine Section at the National Heart, Lung, and Blood Institute in Bethesda, Maryland. He career has focused on the epidemiology, pathogenesis, and management of bronchiectasis and chronic airway infection especially with nontuberculous mycobacteria. He has had a particular interest in genetic defects which alter airway and systemic host defenses and predispose to infection with environmentally transmitted organisms.
Download COI Disclosure

O’Neill Brenda

Dr Brenda O’Neill PhD, MCSP

Affiliation: Senior Lecturer in Physiotherapy, Centre for Health and Rehabilitation Technologies (CHaRT), Institute Nursing and Health Research, Ulster University

Dr Brenda O’Neill is a Senior Lecturer in Physiotherapy. She has extensive clinical experience, and is actively involved in research and development in respiratory health in collaboration with the HPSSPS and international colleagues. Her research areas are Chronic Obstructive Pulmonary Disease, pulmonary rehabilitation, exercise, physical activity, rehabilitation after critical illness, oxygen therapy, Bronchiectasis, patient education and self management. She completed her PhD in 2005 on the topic of oxygen therapy, and was awarded a Distinguished Research Award from the University of Ulster in 2006. She has also won awards such as the Northern Ireland Healthcare Award in 2003 and 2008 for Respiratory COPD project of the year award in secondary care, and was highly commended for the British Thoracic Award for innovation and excellence in education and 2012.
She has over 50 publications and has obtained funding from a range of sources towards research and development in respiratory health e.g. GAIN 2009, Northern Ireland Chest Heart and Stroke Association, 2005, 2011; HSC RDO 2014. She has successfully supervised PhD and MSc students, and contributes to several editorial activities.

Download COI Disclosure

O’Neill Katherine

2013- present Queen’s University Belfast, Centre for Experimental Medicine and Northern
Ireland Clinical Research Facility
Post-doctoral Clinical Research Fellow (0.5 Centre for Experimental
Medicine/0.5 Northern Ireland Clinical Research Facility)• Demonstrated innovative research methodologies
• Lead on set up management of Belfast Lung clearance Index facility; delivering training, certification and quality control services
• Involvement in large multicentre international collaborative projects including the BronchUK partnership and IMI iABC programme
• Delivery of lecture and seminar teaching first year BSc Physiotherapy students
• Formal supervision of research project summer studentships and intercalated students2010- 2013: Queen’s University Belfast, Centre for Infection and Immunity
PhD Student2008 –2010: Belfast Health and Social Care Trust
Northern Ireland Clinical Research Network (NICRN)
Research Physiotherapist Band 6 (Respiratory)2006 – 2008: Belfast Health and Social Care Trust
Research Physiotherapist Band 5 (Respiratory)2006 – 2006: University of Ulster, Health & Rehabilitation Sciences Research Institute
Respiratory Physiotherapy Research Assistant
2010-2014 Queen’s University Belfast, Centre for Infection and Immunity
Ph.D in Medicine
Thesis Title: Lung Clearance Index in Cystic Fibrosis
Supervisors: Prof J. Stuart Elborn, Prof Michael Tunney and Prof Judy Bradley
2010-2011 Queen’s University Belfast, Centre for Infection and Immunity
Medical Statistics 20 point module (Distinction 73%)
2009-2010 University of Ulster, School of Health Sciences
Respiratory Care Physiotherapy 30 point module (Distinction 72%)
2002-2006 University of Ulster, School of Health Sciences
B.Sc. (Hons) Physiotherapy [2.1]
Download COI Disclosure

Polverino Eva

polverino Doctor of Medicine in Cardiopulmonary Pathophysiology from the University of Pisa (Italy). Specialist in respiratory medicine she is involved in the field of respiratory infections and particularly in Community Acquired Pneumonia (CAP), noncystic fibrosis bronchiectasis (NCFB) and humoral immuno-deficiencies. She investigates epidemiology, risk factors, outcome, treatment and prevention of the most relevant respiratory infections. In the field of bronchiectasis she has been investigating the microbiological causes of exacerbations (pneumonia and simple exacerbations) and the application of respiratory physiotherapy to improve airways clearance and fatigue in this chronic and debilitating disease.
Despite the enormous advances in antibiotic therapy CAP is still a very prevalent disease worldwide with a considerable morbidity and mortality. Main efforts of the projects she carries on in this line of research are directed at monitoring epidemiological and clinical changes of the disease and evaluating strategies of better disease control and prevention with special attention to some risk classes of patients such as elderly and long term care facility residents (Healthcare associated pneumonia, HCAP).
In the field of bronchiectasis main objectives are focused on investigation of the prevalence and outcomes of this under estimated but very frequent disease and its impact on the society. In particular the real prevalence and clinical endpoints of NCFB (i.e. quality of life, chronic expectoration) in the general population are still unclear although there are data suggesting that the disease could be as prevalent as COPD.
Humoral immuno-deficiencies are part of a group of rare immunological disorders causing recurrent respiratory infections whose genetics is still barely known. In this line new therapeutic approaches are tested and several collaboration projects with other institutions are carried out to broaden our knowledge about immunological and genetic disorders possibly involved in the disease.
In summary, the results of her research are aimed at investigating pathogenetic mechanisms of respiratory infections, improving their clinical outcomes and patients’ quality of life.
Download COI Disclosure

Posthumus Annette

I am a project manager, working as a contractor in Due Diligence at this moment.. I am participating in the ELF patient advisory group which is developing an educational platform for patients, healthcare professionals and other persons concerned. Diagnosed with BE as a young child. There was hardly any information about BE for many years. Therefore I am very pleased with all the initiatives to gain more knowledge about this disease. Hope my and the other patients contributions help this process.

Scuri Mario

Cv and photo not available

Thomson Rachel

Associate Professor Rachel Thomson MBBS Grad Dip (Clin Epi) PhD FRACP

Dr Rachel Thomson is a Respiratory Physician and clinical researcher working at Greenslopes Private Hospital and the Gallipoli Medical Research Institute (University of Queensland) in Brisbane, Australia. She also conducts specialised mycobacterial clinics at The Prince Charles and Princess Alexandra Hospitals. Dr Thomson received her undergraduate degree from the University of Queensland, and completed physician training in respiratory medicine in Brisbane, Australia and is a fellow of the Royal Australasian College of Physicians. After completing her training, she obtained a Graduate Diploma in Clinical Epidemiology and Biostatistics through the University of Newcastle, followed by a PhD entitled “Characteristics of nontuberculous mycobacteria from a municipal water distribution system and their relevance to human infections” for which she received a QUT Vice Chancellors Outstanding Thesis award.

Dr Thomson is a member of the Australia Bronchiectasis Registry steering committee. She has been an active member of the Thoracic Society of Australia and New Zealand, American Thoracic Society, the Queensland TB expert advisory group, and the ERS NTM-net consilium.

Her current research focuses on the clinical, microbiological and geospatial epidemiology of NTM, immunological susceptibility to NTM infection, and characteristics of the lung microbiome in NTM and bronchiectasis.

Download COI Disclosure

Tiddens Harm

Harm Tiddens is a Professor in pediatric pulmonology at the ErasmusMC-Sophia Children’s Hospital and at the department of radiology.
He is heading the research of the Sophia CF-center and of the ErasmusMC Lung Imaging Group focussing on the development of novel outcome measures for chronic lung diseases. He founded and is heading the ErasmusMC core laboratory LungAnalysis.
He is a visiting professor at the Princess Margaret Hospital for Children in Perth as well as at Ningxia University, Yinchuan, China. He is editorial board member for Pediatric Pulmonology and regular reviewer for major respiratory journals and funding bodies. He is board-member of ECFS and has been co-initiator and co-organiser of the ERS-ECFS basic and advanced CF course and of the ECFS-CTN. He published over 150 papers in peer reviewed journals and contributed chapters to over 30 books.
Download COI Disclosure

Torres Antoni

Antonio Torres is Director of Institut Clínic de Pneumologia i Cirurgia Toràcica of Hospital Clínic de Barcelona (from 2000) and Senior Consultant (from 2001) and was made Associate Professor (Pulmonology), Facultad de Medicina, Universidad de Barcelona in 1991.
He is a physician with a national and international impact and is particularly interested in pulmonary infections; pneumonia, COPD, bronchiectasia and immuno-suppressed, withdrawal of mechanical ventilation, non-invasive mechanical ventilation and acute respiratory distress syndrome.
Antonio Torres published 192 reviews and guidelines.
Download COI Disclosure

Van Ingen Jakko

Jakko van Ingen is a clinical microbiologist, specializing in mycobacteriology. He is the head of the mycobacteriology laboratory at the department of Medical Microbiology at Radboud University Medical Center and an international consultant on treatment of mycobacterial disease. In 2009, he was awarded a PhD with honors at Radboud University Nijmegen for his thesis “Nontuberculous mycobacteria; from gene sequences to clinical relevance”.
His current research focuses on designing new antibiotic treatment regimens for nontuberculous mycobacterial disease. He has built a preclinical development track of minimum inhibitory concentration measurements, synergy tests, time-kill kinetic assays and ultimately a hollow fiber pharmacodynamic model to simulate infection and treatment.
Download COI Disclosure

Welte Tobias

Professor Tobias Welte is the Head of the Department of Respiratory Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover.
1978 -1985: Study of human medicine, Hannover Medical School
1985 – 88/90: Department of Internal Medicine, County Hospital Lehrte
1989: Residentialship, Massuchusetts General Hospital Boston, USA
1990-1994: Fellow, Department of Respiratory Medicine, Hannover Medical School
1992: Specialist for Internal Medicine
1994: Specialist for Respiratory Medicine
1994: MD
1995: Specialist Intensive Care Medicine
2000: Habilitation for “Internal Medicine”
2002: Specialist for Infectious Disease Academic Appointments:
1994 – 2004 : Head of the Division of Respiratory Medicine and Intensive Care, University of Magdeburg
2003: Appointment C3 Professorship for Respiratory Medicine University of Magdeburg, not accepted
since 2004: W3-Professorship, Head of the Department of Respiratory Medicine, Hannover Medical School
2015: Appointment Professorship for Pneumology, University of Vienna, not accepted Other (selected) Professional Activities:
1994 – today: Project leader in more than thirty research projects funded by DFG, BMBF and EU
Since 2001: Co-ordinating board of BMBF-competence networks PROGRESS, ASCONET and CAPNETZ as well as Chairman of CAPNETZ Foundation
2007-2011: Speaker of the BMBF funded Clinical Study Center Hannover (KS-MHH)
since 2011: Member of the board of directors of the German Center for Lung Research (DZL) and director of the Hannover DZL site BREATH (Biomedical Research in Endstage and Obstructive Lung Disease Hannover)
since 2011: Member of the Internal Advisory Board of the German Center of Infectious Disease Research (DZIF)
2008-2010: President of the German Society of Medical Intensive Care Medicine
2009-2015: Chief Editor of the European Respiratory Monograph
since 2008: Member, since 2012 Spokesman of DFG-Fachkollegium “Inflammation”
2009-2013: President of the German Sepsis Society
2012-2014 President of German Society of Pneumology
Additional Information: 2014 Appointment as Fellow of the European Respiratory Society (FERS)
Download COI Disclosure


Oral presentation

Membrado Lope Oscar

I have just finished the physiotherapy degree offered by Universidad San Jorge, in Zaragoza Spain.
In my last degree year I was awarded a research scholarship which allowed me to join the Cardiorespiratory Rehabilitation line of research belonging to “iPhysio” a research group. My research focuses on the study of the sensitivity of the respiratory sounds computerised analysis to detect changes in patients with bronchiectasis, more specifically in his ability to detect changes to bronchial drainage tecniques.
Download COI Disclosure

Shteinberg Michala

Michal Shteinberg is an adult Pulmonology and CF consultant at the Carmel MC Pulmonology Institute and CF center, and a clinical lecturer at the B. Rappaport Faculty of Medicine, Technion- Israel Institute of Technology.
Dr. Shteinberg’s main clinical and research interests are bronchietasis and adult cystic fibrosis. She runs a referral clinic with over 300 patients with bronchiectasis, which offers a multidisciplinary team. Her research focuses on the phenotypes of bronchiectasis with upper airway involvement and mycobacterial infection in bronchiectasis, implementing physiotherapy in patients with bronchiectais, and on clinical manifestations of adults with CF .
Dr. Shteinberg is the Israeli representative for EMBARC, and led the development of the Israeli Pulmonology and and Pediatric Pulmonology Societies’ joint Position Paper on diagnosis and treatment of patients with bronchiectais. She is active in promoting coverage for medications for patients with bronchiectasis.
Download COI Disclosure

Taylor Steven

Steven Taylor is a PhD candidate in the Microbiome Research theme at the South Australian Health and Medical Research Institute (SAHMRI), supervised by Assoc. Prof. Geraint Rogers, and Prof. Steve Wesselingh. Steven’s has a background in mucosal immunology and microbiology with a research focus on understanding the interactions between the microbiome and the respiratory tract during health and respiratory disease.
Download COI Disclosure


Rising Star

Athanazio Rodrigo

Rodrigo Athanazio graduated in Medical School in 2005 and followed specialization in Internal Medicine and Pulmonology. In 2010, started a fellowship in obstructive lung diseases in the Heart Institute (InCor) of the University of São Paulo – Brazil. After 2 years, he was admitted as a medical and research assistant of the University of São Paulo with special interest in airway diseases, mainly bronchiectasis, adult cystic fibrosis and severe asthma. In 2016, he received his PhD degree and continued to play his role in the academic field with new projects focusing mainly on the behavior of pulmonary function, small airways involvement and rehabilitation in obstructive lung diseases including bronchiectasis and cystic fibrosis.
Download COI Disclosure

Anna Mulholland

Dr Anna Mulholland is an Advanced Trainee in Paediatric Respiratory and General Paediatric medicine. She is currently a Paediatric Respiratory Fellow training at the Starship Children’s Hospital in Auckland, New Zealand. She has also spent time during her training in Australia and provincial New Zealand. She developed an interest in respiratory paediatrics after experiencing the prevalence and severity of acute and chronic respiratory disease in New Zealand. Her current research involves the study of the airway microbiome in children with acute respiratory infections such as bronchiolitis and pneumonia and in children with non-CF bronchiectasis.
Download COI Disclosure

Guillermo Suarez-Cuartin M.D.

Guillermo Suarez-Cuartin M.D. is a consultant of the respiratory department at the Hospital de la Santa Creu i Sant Pau in Barcelona, Spain. After completing his clinical training in respiratory medicine he has been involved in translational research of respiratory infections, mainly focused on bronchiectasis patients. He is currently finishing his PhD at the Universitat Autonoma de Barcelona on the topic of new diagnostic methods for Pseudomonas aeruginosa airway colonization in bronchiectasis. He has been awarded with fellowship awards from the Catalan and Spanish Respiratory Societies (SOCAP and SEPAR), and is the author of international peer-reviewed papers.
Download COI Disclosure

Dejan Radovanovic

“Dejan Radovanovic is a fellow of the School of Respiratory Diseases of the University of Milan (Italy). His main research interests include lung pahophysiology and mechanics, heart-lung interaction, pulmonary pharmacology and respiratory muscles. He authored and co-authored several papers on national and international peer-reviewed journals, together with book chapters and reviews. He serves also as reviewer for many international peer-reviewed journals”.
Download COI Disclosure